Leash Biosciences, a Salt Lake City, UT-based artificial intelligence and machine learning (AI/ML)-native biotechnology company, raised $9.3M in Seed funding.
The round was led by Springtide Ventures with participation from MetaPlanet, Top Harvest Capital, Mitsui Global Investment, MFV Partners, Recursion co-founders Chris Gibson, and Blake Borgeson.
The company intends to use the funds to support development of a foundational machine learning model of medicinal chemistry that can predict small molecule drug candidates for any protein.
Led by CEO Ian Quigley, Leash Biosciences is a biotechnology company unleashing machine learning to solve medicinal chemistry. Through the combination of machine learning and chemical and biological datasets, the company works to rapidly design novel small molecule therapeutics.
To date, Leash has physically generated over 17 billion high-quality protein-chemical interaction measurements. In its new Salt Lake City headquarters, the company plans to screen 500+ protein targets against many millions of machine learning-designed, proprietary chemicals by 2025.
FinSMEs
08/04/2024